Phospholipids pp 177-183 | Cite as

Phospholipids in Oncology

  • Dieter Arndt


Phospholipids are, besides glycolipids, cholesterol and proteins, the main components of biological membranes. Membrane phospholipids are possibly involved in differences between normal cells and tumor cells. Furthermore, phospholipids in the cell membrane may be plausible targets for anticancer agents. A few phospholipids, especially etherlipids, are very promising anticancer agents and, finally, phospholipids are important as the main bilayer component for the encapsulation of anticancer drugs in liposomes.


Anticancer Drug Ether Lipid Cellular Oncogene Liposomal Encapsulation Macrophage Activation Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alving, C.R., 1987, Liposome techniques in cell biology, Nature 330:189–190.CrossRefGoogle Scholar
  2. 2.
    Arndt, D., and Fichtner, I., 1986, “Liposomen — Darstellung, Eigenschaften, Anwendung”, Akademie-Verlag, Berlin.Google Scholar
  3. 3.
    Arndt, D., Hülsmann, W., and Schwabe, K., 1986, Resistenz gegenüber antineoplastischen Substanzen, in.: “Allgemeine und spezielle Tumorchemotherapie”, St. Tanneberger, ed., Akademie-Verlag, Berlin.Google Scholar
  4. 4.
    Berger, M.R., Schmaehl, D., Muschiol, C., Unger, C., and Eibl, H., 1986, Alkylphosphocholines as anticancer agents, J. Cancer Res. Clin. Oncol., 111: S24.CrossRefGoogle Scholar
  5. 5.
    Brachwitz, H., Langen, P., Arndt, D., and Fichtner, I., 1987, Cytostatic activity of synthetic O-alkylglycerolipids, Lipids 22:897–903.PubMedCrossRefGoogle Scholar
  6. 6.
    Creaven, P.J., Brenner, D.E., Cowens, J.W., Hüben, R., Karakousis, C., Han, T., Dadey, B., Andrejcio, K., and Cushman, M.K., 1989, Initial clinical trial of muramyl tripeptide derivative (MTP-PE) encapsulated in liposomes: An interim report, in: “Liposomes in the therapy of infections diseases and Cancer”, G. Lopez-Berestein, I.J., Fidler, Eds., Alan R. Liss, Inc., New York.Google Scholar
  7. 7.
    Eibl, H., 1984, Phospholipide als funktioneile Bausteine biologischer Membranen, Angew. Chem. 96:247–262.CrossRefGoogle Scholar
  8. 8.
    Fichtner, I., and Arndt, D., 1989, Stand und Perspektiven der Liposomen-forschung, Pharmazie 44:752–757.PubMedGoogle Scholar
  9. 9.
    Fidler, I.J., and Schroit, A.S., 1988, Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self, Biochim. Biophys. Acta 948:151–173.PubMedGoogle Scholar
  10. 10.
    Firth, G.P., Firth, M., McKeran, R., Rees, J., Walter, P., Uttley, D., and Marks, V., 1988, Application of radioimmunoassy to monitor treatment of human cerebral gliomas with bleomycin entrapped within liposomes, J. Clin. Pathol. 41:38–45.PubMedCrossRefGoogle Scholar
  11. 11.
    Gabizon, A., Sulkes, N., Peretz, T., Druckmann, S., and Barenholz, Y., 1989, Liposome-associated doxorubicin: Preclinical pharmacology and exploratory clinical phase 1,2, in: “Liposomes in the therapy of infections diseases and cancer”, G. Lopez-Berestein, I.J. Fidler, eds., Alan R. Liss, Inc., New York.Google Scholar
  12. 12.
    Goormaghtigh, E., and Ruysschaert, J.M., 1984, Anthracycline glycoside membrane interactions, Biochim. Biophys. Acta 779:271–288.PubMedCrossRefGoogle Scholar
  13. 13.
    Gregoriadis, G., ed., 1988, Liposomes as drug carriers — Recent trends and progress, J. Wiley, Chichester.Google Scholar
  14. 14.
    Grunicke, H., Doppler, W., Hofmann, J., Lindner, H., Maly, K., Oberhuber, H., Ringsdorf, H., and Roberts, J.J., 1986, Plasma membrane as target of alkylating agents, Advances in Enzyme Regulation 24:247–261.CrossRefGoogle Scholar
  15. 15.
    Gustin, A.S., Leaf, E.B., Shipley, G.D., and Moses, H.L., 1986, Growth factors and cancer, Cancer Res. 46:1015–1029.Google Scholar
  16. 16.
    Hanagan, J.R., Trunet, P., LeSher, D., Andrejcio, K., and Frost, H., 1989, Phase I development of CGP 19835A lipid (MTP-PE encapsulated in liposomes), in: “Liposomes in the therapy of infections diseases and cancer”, G. Lopez-Berestein, I.J. Fidler, eds., Alan R. Liss, Inc., New York.Google Scholar
  17. 17.
    Heuser, L.S., and Miller, F.N., 1986, Differential macromolecular leakage from the vasculature of tumors, Cancer 57:461–464.PubMedCrossRefGoogle Scholar
  18. 18.
    Kleinermann, E.S., and Hudson, M.M., 1989, Liposome therapy: Anovel approach to the reatment of childhood osteosarcoma, in: “Liposomes in the therapy of infections diseases and cancer”, G. Lopez-Berestein, I.J. Fidler, eds., Alan R. Liss, Inc., New York.Google Scholar
  19. 19.
    Lopez-Berestein, G., Bodey, G.P., Frankel, L.S., and Mehta, K., 1987, Treatment of hepatosplenic candidiasis with liposomal-amphotericin B, J. Clin. Oncol. 5:310–317.PubMedGoogle Scholar
  20. 20.
    Lopez-Berestein, G., Kasi, L., Rosenblum, M.G., Haynie, T., Jahns, M., Glenn, H., Mehta, R., Mavligit, G.M., and Hersh, E.N., 1984, Clinical pharmacology of Tc-labeled liposomes in patients with cancer, Cancer Res. 44:375–378.PubMedGoogle Scholar
  21. 21.
    Morere, J.F., Israel, L., Puisieux, F., Breau, J., Durieux, J., and Sponton, E., 1986, Phase I trial of systemic and regional muramyldipeptide (MDP) liposomes in cancer patients with advanced neoplasms, Proc. ASCO 5: 220.Google Scholar
  22. 22.
    Nishizuka, Y., 1986, Studies and perspectives of protein kinase C., Science 233:305–312.PubMedCrossRefGoogle Scholar
  23. 23.
    Poste, G., 1986, Pathogenesis of metastatic disease: Implications for current therapy and for the development of new therapeutic strategies, Cancer Treatm. Rep. 70:183–199.Google Scholar
  24. 24.
    Rahman, A., Roh, J.-K., and Treat, J., 1989, Preclinical and clinical pharmacology of doxorubicin entrapped in cardiolipin liposomes, in: “Liposomes in the therapy of infections diseases and cancer”, G. Lopez-Berestein, I.J. Fidler, Eds., Alan R. Liss, Inc. New York.Google Scholar
  25. 25.
    Ramu, A., Glaubiger, D., and Weintraub, H., 1984, Differences in lipid composition of doxorubicin-sensitive and-resistant P 388 cells, Cancer Treatm. Rep. 68:637–641.Google Scholar
  26. 26.
    Sculier, J.P., Coune, A., Brassinne, C., Laduron, C., Atassi, G., Ruyschaert, J.M., and Frühling, J., 1986, 1986, Intravenous infusion of high doses of liposome containing NSC 251635, a water-insoluble cytostatic agent. Apilot study with pharmacokinetic data, J. Clin. Oncol. 4:789–797.PubMedGoogle Scholar
  27. 27.
    Sculier, J.P., Coune, A., Meunier, F., Brassinne, C., Laduron, C., Houlaert, C., Collette, N., Heymans, C., and Klastersky, J., 1988, Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections, Eur. J. Cancer Clin. Oncol. 24:527–538.PubMedCrossRefGoogle Scholar
  28. 28.
    Sells, R.A., Gilmore, I.T., Owen, R.R., New, R.R.C., and Stringer, R.E., 1987, Reduction in doxorubicin toxicity following liposomal delivery, Cancer Treatm. Rev. 14: 383.CrossRefGoogle Scholar
  29. 29.
    Shinitzky, M., 1979, Passive modulation of membrane proteins, in: “Physical and chemical aspects of cell surface events and cellular regulation”, R. Blumenthal, C. de Lisi, eds., Elsevier/North Holland, Amsterdam.Google Scholar
  30. 30.
    Special Issue, 1987, Ether lipids in oncology, Lipids 22: No 11.Google Scholar
  31. 31.
    Spector, A.A., and Burns, C.P., 1987, Biological and therapeutical potential of membrane lipid modification in tumors, Cancer Res. 47:4529–4537.PubMedGoogle Scholar
  32. 32.
    Treat, J., Greenspan, A.R., and Rahman, A., 1989, Liposome encapsulated doxorubicin preliminary results of phase I and phase II trials, in: “Liposomes in the therapy of infections diseases and cancer”, G. Lopez-Berestein, I.J. Fidler, eds., Alan R. Liss, Inc., New York.Google Scholar
  33. 33.
    Tritton, T.R., and Yee, G., 1982, The anticancer agent adriamycin can be actively cytotoxic without entering cells, Science 217:248–250.CrossRefGoogle Scholar
  34. 34.
    Zeisig, R., Arndt, D., and Brachwitz, H., 1990, Etherlipide-Synthese und tumortherapeutische Verwendbarkeit, Pharmazie 45: in press.Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Dieter Arndt
    • 1
  1. 1.Academy of Sciences of German Democratic RepublicCentral Institute of Cancer Research GDRBerlin-BuchGermany

Personalised recommendations